Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.

ABSTRACT: Irreproducibility of preclinical findings could be a significant barrier to the "bench-to-bedside" development of oncolytic viruses (OVs). A contributing factor is the incomplete and non-transparent reporting of study methodology and design. Using the NIH Principles and Guidelines for Reporting Preclinical Research, a core set of seven recommendations, we evaluated the completeness of reporting of preclinical OV studies. We also developed an evidence map identifying the current trends in OV research. A systematic search of MEDLINE and Embase identified all relevant articles published over an 18 month period. We screened 1,554 articles, and 236 met our a priori-defined inclusion criteria. Adenovirus (43%) was the most commonly used viral platform. Frequently investigated cancers included co

SUBMITTER: Fergusson DA 

PROVIDER: S-EPMC6586991 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature